EICHORCondition: Contrast Induced Acute Kidney Injury · Sponsor: Aptabio Therapeutics, Inc.
This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 230 patients will be randomized into the study in a 1:1 ratio to 400 mg APX-115 (Isuzinaxib hydrochloride) or placebo arm.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Baylor Scott & White Research Institute | Dallas, Texas, United States | — |
| Kangwon National University Hospital | Chuncheon, South Korea | — |
| Keimyung University Dongsan Hospital | Daegu, South Korea | — |
| Chungnam National University Hospital | Daejeon, South Korea | — |
| Inje University Ilsan Paik Hospital | Goyang, South Korea | — |
| Chonnam National University Hospital | Gwangju, South Korea | — |
| Seoul National University Bundang Hospital | Seongnam-si, South Korea | — |
| Kangbuk Samsung Hospital | Seoul, South Korea | — |
| Korea University Anam Hospital | Seoul, South Korea | — |
| Samsung Medical Center | Seoul, South Korea | — |
| Seoul National University Hospital | Seoul, South Korea | — |
| The Catholic University of Korea Seoul St. Mary's Hospital | Seoul, South Korea | — |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05758896